La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Scorpius Holdings Dividende

Dividende contrôle des critères 0/6

Scorpius Holdings n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	1.9%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$9.49
Prévision de rendement du dividende	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de SCPX ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de SCPX ont augmenté.

Rendement des dividendes par rapport au marché

Scorpius Holdings Rendement des dividendes par rapport au marché

Comment le rendement du dividende de SCPX se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (SCPX)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.3%
Moyenne du secteur (Biotechs)	1.9%
Analyste prévisionnel (SCPX) (jusqu'à 3 ans)	n/a

Dividende notable: Impossible d'évaluer le rendement des dividendes de SCPX par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de SCPX par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de SCPX afin de déterminer si ses paiements de dividendes sont couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car SCPX n'a signalé aucun versement.

Scorpius Holdings Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

NYSE American Withdraws Delisting Determination of Scorpius Holdings Common Stock

Scorpius Holdings Set to Launch First Mammalian Cgmp Campaign At San Antonio Facility in the 2024 3Rd Quarter

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.

Scorpius Holdings, Inc Successfully Executes First cGMP Microbial Batches at San Antonio Facility

NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Scorpius Holdings, Inc. Provides Non-Compliance Update

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million.

Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc.

Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings, Inc. announced delayed annual 10-K filing

Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Price target decreased by 9.1% to US$10.00

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK).

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced delayed 10-Q filing

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board

Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc.

Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020)

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Price target decreased to US$21.83

Price target decreased to US$23.83

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients

Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Independent Lead Director recently sold US$205k worth of stock

Consensus forecasts updated

Consensus revenue estimates fall to US$1.98m

Heat Biologics names Anthony Manning as chief scientific advisor

Price target decreased to US$24.67

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.77 loss in 1Q 2020)

Heat Biologics EPS misses by $0.01, misses on revenue

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Full year 2020 earnings released: US$1.63 loss per share (vs US$4.21 loss in FY 2019)

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Heat Biologics, Inc. Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics, Inc. Announces Publication of Additional Preclinical COVID-19 Vaccine Results

New 90-day high: US$8.76

Price target lowered to US$27.30

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. Announces the Promotion of William Ostrander to Chief Financial Officer

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés